Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 plus carboplatin + nab-paclitaxel versus chemotherapy alone as first-line treatment for advanced squamous NSCLC
2019-003064-50Phase 3Completed
- Sponsor
- Henlius
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of serplulimab in Pulmonary squamous cell carcinoma (2 arms), sponsored by Henlius. Primary endpoint: Primary efficacy endpoint. Started Mar 2020; status: completed.
02
Drugs
serplulimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2019-003064-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003064-50.